Published in J Nucl Med on August 01, 1997
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med (2010) 1.98
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol (2009) 1.24
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med (2011) 1.07
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging (2013) 1.05
FDG PET in Prostate Cancer. PET Clin (2009) 0.89
Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis (2014) 0.82
Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. Eur J Nucl Med Mol Imaging (2007) 0.78
Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs (2003) 0.76
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Microbial communities of continuously cropped, irrigated rice fields. Appl Environ Microbiol (1997) 2.83
Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med (1997) 2.42
In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res (1980) 2.40
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med (1991) 2.09
Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology (1994) 2.05
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med (2001) 2.01
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88
Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A (1981) 1.87
Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging (1999) 1.81
Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther (2008) 1.66
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med (1995) 1.65
Renal arteries: optimization of three-dimensional gadolinium-enhanced MR angiography with bolus-timing-independent fast multiphase acquisition in a single breath hold. Radiology (1999) 1.58
Functions encoded by pyrrolnitrin biosynthetic genes from Pseudomonas fluorescens. J Bacteriol (1998) 1.54
Quantification of [(18)F]FDG uptake in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply. J Nucl Med (2001) 1.49
Changes in myocardial oxygenation and perfusion under pharmacological stress with dipyridamole: assessment using T*2 and T1 measurements. Magn Reson Med (1999) 1.48
MR imaging of fat-containing tissues: valuation of two quantitative imaging techniques in comparison with localized proton spectroscopy. Magn Reson Imaging (1993) 1.41
Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer (2003) 1.38
[Quality assurance in roentgen mammography. Comparison of recommended EUREF guidelines with relevant German regulations]. Radiologe (1997) 1.38
Hippocampal malrotation with normal corpus callosum: a new entity? Neuroradiology (2000) 1.34
Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci U S A (1982) 1.31
Classification of signal-time curves from dynamic MR mammography by neural networks. Magn Reson Imaging (2001) 1.30
Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol (2001) 1.29
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie (2002) 1.28
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med (2010) 1.24
Acquired renal cysts in uremic patients--in vivo demonstration by computed tomography. Clin Nephrol (1980) 1.22
Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med (2001) 1.19
[5 years of "concerted action dose reduction in CT" -- what has been achieved and what remains to be done?]. Rofo (2004) 1.17
Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res (1998) 1.17
New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer (1992) 1.16
PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med (1991) 1.15
Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res (1998) 1.14
Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging (1999) 1.14
Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res (2001) 1.12
[Reduction of radiation exposure in PET examinations by data acquisition in the 3D mode]. Nuklearmedizin (1999) 1.12
FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol (1994) 1.11
Investigation of scattered radiation in 3D whole-body positron emission tomography using Monte Carlo simulations. Phys Med Biol (1999) 1.09
Recurrence of colorectal tumors: PET evaluation. Radiology (1989) 1.07
Use of scanner characteristics in iterative image reconstruction for high-resolution positron emission tomography studies of small animals. Eur J Nucl Med (1997) 1.07
MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am (1994) 1.07
Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases. Cancer Res (1982) 1.06
Fast fluid-attenuated inversion-recovery (FLAIR) MRI in the assessment of intraaxial brain tumors. J Magn Reson Imaging (1998) 1.05
Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: the first Multicentre Study in Germany. Alcohol Alcohol (2001) 1.05
Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res (1997) 1.04
Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology (2002) 1.04
MRI of capillary hemangioma of the testis. J Comput Assist Tomogr (1997) 1.04
Diagnostic accuracy of computerized B-scan texture analysis and conventional ultrasonography in diffuse parenchymal and malignant liver disease. J Clin Ultrasound (1985) 1.04
Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol (1996) 1.03
Monitoring gene therapy with herpes simplex virus thymidine kinase in hepatoma cells: uptake of specific substrates. J Nucl Med (1997) 1.02
Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys (2001) 1.02
Correction of spatial distortion in magnetic resonance angiography for radiosurgical treatment planning of cerebral arteriovenous malformations. Magn Reson Imaging (1992) 1.01
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol (2000) 1.00
Bicarbonate permeability of epithelial chloride channels. Pflugers Arch (1991) 1.00
Child care centers: a community resource for injury prevention. J Dev Behav Pediatr (1993) 1.00
Comparison of rigid and elastic matching of dynamic magnetic resonance mammographic images by mutual information. Med Phys (2000) 0.99
Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer (2001) 0.99
Stereotactic single high dose radiation therapy of benign intracranial meningiomas. Int J Radiat Oncol Biol Phys (1990) 0.98
Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys (1998) 0.98
Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med (2001) 0.98
Cerebral arteriovenous malformations: improved nidus demarcation by means of dynamic tagging MR-angiography. Magn Reson Imaging (1996) 0.96
Functional MR imaging of semantic information processing and learning-related effects using psychometrically controlled stimulation paradigms. Brain Res Cogn Brain Res (1996) 0.96
A novel method for real-time magnetic marker monitoring in the gastrointestinal tract. Phys Med Biol (2000) 0.95
Breast tumors: computer-assisted quantitative assessment with color Doppler US. Radiology (1994) 0.95
Multiexponential proton spin-spin relaxation in MR imaging of human brain tumors. J Comput Assist Tomogr (1989) 0.95
Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. MAGMA (1999) 0.95
Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol (2004) 0.95
Staging of invasive cervical carcinoma and of pelvic lymph nodes by high resolution MRI with a phased-array coil in comparison with pathological findings. J Comput Assist Tomogr (1998) 0.95
Renal artery stenosis: grading of hemodynamic changes with cine phase-contrast MR blood flow measurements. Radiology (1997) 0.94
Mapping of a further locus for X-linked craniofrontonasal syndrome. Cytogenet Genome Res (2002) 0.94
Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient-echo imaging. J Comput Assist Tomogr (1994) 0.94
Cerebral gliomas and metastases: assessment with contrast-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology (1999) 0.94
Computerized ultrasound B-scan texture analysis of experimental diffuse parenchymal liver disease: correlation with histopathology and tissue composition. J Clin Ultrasound (1991) 0.94
Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med (2001) 0.93
BOLD-MRI in ten patients with coronary artery disease: evidence for imaging of capillary recruitment in myocardium supplied by the stenotic artery. MAGMA (1999) 0.93
Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J Gen Virol (1997) 0.92
Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Anticancer Drugs (1995) 0.91
Age dependency of the regional cerebral blood volume (rCBV) measured with dynamic susceptibility contrast MR imaging (DSC). Magn Reson Imaging (1996) 0.91